CEO Today Business Women Awards 2023 SWITZERLAND ABOUT MYRIAM Myriam joined Selexis in 2012 as project leader, managing and coordinating research, experimental design, process completion, data treatment and reporting for partner projects. Subsequently, she held roles of increasing responsibility, serving as scientist in vector engineering and later as operations program manager and operations director, coordinating partner-oriented mammalian cell line generation and whole-genome sequencing programs. In the latter roles, Myriam also supported intellectual property activities. Previously, she was scientist at École Polytechnique fédérale de Lausanne (EPFL) and project leader, gene expression and analytics at ExcellGene SA. She held postdoctoral positions at Centre of Immunology Marseille-Luminy, University of Geneva-CMU and Geneva Hospital. Myriam earned her PhD in botanical sciences from the University of Liège, Belgium. SELEXIS SA At our core, Selexis is a company of dreamers and adventurers — thoughtful risk-takers willing to travel the difficult road to empower innovation in drug development and ultimately transform the care of and prospects for millions of patients who suffer from life-threatening diseases. Our journey began in 2001 when our Company was formed behind an ambitious vision: to change how biologic drugs are developed. We’re very proud of what we have accomplished during the past 20 years in translating basic gene expression technologies into a unique platform that is used by more than 100 leading companies worldwide. CEO Selexis SA MYRIAM ADAM
RkJQdWJsaXNoZXIy Mjk3Mzkz